Clinical Research Directory
Browse clinical research sites, groups, and studies.
LRFN5 and OLFM4 in Schizoaffective Disorder
Sponsor: Elazığ Mental Health and Diseases Hospital
Summary
Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging evidence suggests that Leucine-Rich Repeat and Fibronectin Type-III Domain-Containing Protein 5 (LRFN5) and olfactomedin-4 (OLFM4) may play roles in synaptic organization, neurodevelopment, and neuroinflammation. However, no prior study has investigated these biomarkers in SAD. This cross-sectional case-control study aims to compare peripheral serum levels of LRFN5 and OLFM4 in subjects diagnosed with SAD in remission and healthy control subjects. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in SAD.
Official title: LRFN5 and OLFM4 Levels in Schizoaffective Disorder: A Cross-Sectional Case-Control Study
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
OBSERVATIONAL
Enrollment
120
Start Date
2026-03-02
Completion Date
2026-05-29
Last Updated
2026-03-04
Healthy Volunteers
Yes
Conditions
Locations (1)
Elazığ Mental Health and Diseases Hospital Psychiatry Clinic
Elâzığ, Elâzığ, Turkey (Türkiye)